Business Wire

BIO KOREA 2020 International Convention to Go Virtual

Share

BIO KOREA 2020 International Convention, where global bio experts correspond, is shifting to an online-only event.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200424005107/en/

BIO KOREA 2020 will be held as an online convention from May 18 09:00 to 23 18:00. BIO KOREA Organizing Committee has taken its final measures to execute a full digitalization of the event considering the health and safety of its participants and prevention of the further spread of COVID-19 ultimate importance above all other matters concerned. Under the main theme “A New Paradigm in the Age of Data Science”, BIO KOREA 2020 will be held as an online convention, maintaining its five main programs consisting of Conference, Business Forum, Exhibition, Invest Fair, and Job Fair. You can participate on BIO KOREA 2020 Official Website: www.biokorea.org. (Graphic: Business Wire)

BIO KOREA 2020 will be held as an online convention from May 18 09:00 to 23 18:00. BIO KOREA Organizing Committee has taken its final measures to execute a full digitalization of the event considering the health and safety of its participants and prevention of the further spread of COVID-19 ultimate importance above all other matters concerned. Under the main theme “A New Paradigm in the Age of Data Science”, BIO KOREA 2020 will be held as an online convention, maintaining its five main programs consisting of Conference, Business Forum, Exhibition, Invest Fair, and Job Fair. You can participate on BIO KOREA 2020 Official Website: www.biokorea.org. (Graphic: Business Wire)

BIO KOREA Organizing Committee has taken its final measures to execute a full digitalization of the event considering the health and safety of its participants and prevention of the further spread of Coronavirus (COVID-19) ultimate importance above all other matters concerned. In place of hosting an in-person format in Seoul, it will digitally take place over the entire week of May 18 – 23, 2020.

Under the main theme “A New Paradigm in the Age of Data Science”, BIO KOREA 2020 will be held as an online convention, maintaining its five main programs consisting of Conference, Business Forum (Partnering), Exhibition, Invest Fair, and Job Fair.

BIO KOREA 2020 Online Convention – from e-Conference, Online Meeting, and Virtual Exhibition

Regardless of the current outbreak of COVID-19, BIO KOREA 2020 will continue to cater for its participants to its best means. As the five main programs of BIO KOREA (Conference, Business Forum (Partnering), Exhibition, Invest Fair, and Job Fair) are delivered online, its participants can partake in the convention with safety and convenience. Moreover, this pioneering move will greatly enhance the efficiency in terms of time and effort put in by the presenters and all other participants for the preparation and operation of BIO KOREA 2020.

The five main programs of BIO KOREA 2020 will create an arena where in-depth academic knowledge and innovative entrepreneurial ideas are exchanged by way of e-Conference and Online Business Forum with partnering (Online Meeting). Those gems of knowledge and innovation will then be elaborated and visualized by numerous leading bio-companies around the globe in Virtual Exhibition. Not only that, BIO KOREA 2020’s Invest Fair and Job Fair will provide invaluable opportunities for general investors and the public to directly participate into the global bio industry.

BIO KOREA Organizing Committee stated that it is spurring towards preparing BIO KOREA 2020 as an online convention determined to support the information exchange of the bio industry. In addition to its advanced implementation including the operation of VR Zone and Live streaming, the Committee aims to conduct a safe and successful delivery of BIO KOREA 2020 as an online convention, turning the global crisis into opportunity.

BIO KOREA is a place of practical business correspondence as well as international information and technology exchange, invigorating the bio industry. In its 15th year of bringing together various international academics, professionals, and CEOs of global bio companies to obtain, exchange, and discuss diverse affairs, BIO KOREA had been providing abundant opportunities to assure competitive edges within the convergence industry centered around biotechnology.

For more information, visit BIO KOREA’s Official Website: www.biokorea.org and https://www.youtube.com/watch?v=7tYarlZEL0A&feature=youtu.be.

Contact information

BIO KOREA Organizing Committee
Suyeon Choi, Researcher
+82-1661-0810 (O! BIO)
biokorea@biokorea.org

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the 25thEuropean Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR-A

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25thEuropean Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leukemi

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 13:57:00 CESTPress release

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom